ClinicalTrials.gg
RecruitingNCT06672913TR-SSCinNICUUpdated Nov 4, 2024

Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study

An interventional study of skin to skin contact care in Premature, Skin to Skin Contact and Breast Feeding, sponsored by Baskent University Ankara Hospital. Recruiting at 1 site in Turkey. Open to participants aged 1 Day and older. Per ClinicalTrials.gov, last updated 2024-11-04.

Sponsored by Baskent University Ankara Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
1 Day and older
Sex
All
01

Study summary

This study is a multi-center, prospective pre-post clinical study conducted under the leadership of the Turkish Neonatal Society. It aims to investigate the effects of a standardized skin-to-skin care in NICU, initiated early and applied regularly, on recieving exclusive mothers' milk at discharge and clinical outcomes for preterm infants born ≤ 32 weeks of gestation.

  1. Primary Objective: To evaluate the rate of receiving exclusive mothers' milk at discharge for infants born ≤ 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol.
  2. Secondary Objective: To evaluate the rates of neonatal sepsis, intraventricular hemorrhage, and necrotizing enterocolitis (stage 2 and above) as well as the length of hospital stay for infants born at or below 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol.
Read the detailed description
  1. Introduction: Throughout the historical evolution of the field of neonatology, negative consequences of newborns being separated from their families for extended periods while in neonatal intensive care units (NICUs) have been observed. In 1978, the concept of "Skin-to-skin care: Kangaroo Mother Care" was introduced. This model has been recommended by the World Health Organization to replace incubators and radiant warmer technologies in developing and least developed countries, where the capacity of NICUs is very limited. Additionally, in developed countries, where newborn health indicators are optimal, family-centered care and family-integrated care approaches have been used as crucial components to maintain the bond between mothers-and even families-with patients requiring NICU care and premature newborns. Canada in North America and Scandinavian countries in Europe are pioneers of this approach. In developed countries that have adopted this model, regardless of how small, premature, or ill the newborn is, their medical needs are met from birth while ensuring skin-to-skin care with their mother or father. In today's changing architecture of NICUs, care and treatment are conducted in "personalized neonatal intensive care areas for families," with the participation of families.

    Skin-to-skin care has been shown to be effective in improving breastfeeding rates, enhancing bonding, better physiological stability, reducing stress levels, shortening hospital stays, decreasing the risk of infections, lowering rates of intraventricular hemorrhage, and improving weight gain and parental confidence. Additionally, it has been shown to be most effective when skin-to-skin care is applied for more than one hour in a single session and for more than eight hours in a day. This can be best assured if a protocol exists in the units.

  2. Objective: This study is a multi-center, prospective pre-post clinical study conducted under the leadership of the Turkish Neonatal Society. It aims to investigate the effects of a standardized skin-to-skin care application, which is initiated early and applied regularly, on clinical outcomes for preterm infants born at less than 32 weeks of gestation.

    1. Primary Objective: To evaluate the rate of receiving exclusive mothers' milk at discharge for infants born ≤ 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol.
    2. Secondary Objective: To evaluate the rates of neonatal sepsis, intraventricular hemorrhage, and necrotizing enterocolitis (stage 2 and above) as well as the length of hospital stay for infants born at or below 32 weeks of gestation who have received skin-to-skin care in accordance with the study protocol.
  3. Method: Eight training institutions (hospitals) from different geographical regions of Turkiye will be selected. Once the chair of the selected NICUs express their consent to participate, detailed information about the project will be provided to them. The training program developed regarding the skin-to-skin care approach will be delivered in a face-to-face format on a full training day for the responsible physicians and nursing staff working in the units. The theoretical lesson program will consist of three 45-minute lessons (history, standard skin-to-skin care application, skin-to-skin care application for at-risk infants). Practical lessons will be conducted in pairs using a realistic scenario with models. Following the theoretical and practical lessons, the aim is to implement skin-to-skin care based on a standardized protocol for at least one hour per each session, initiated early and regularly.

    a. The skin-to-skin care application proposed by the Turkish Neonatology Association is as follows:

    i. Duration: At least one hour per session

    ii. Time to initiate first skin-to-skin care:

    GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured

    iii. Criteria to accepted as stabilization: Absence of hypothermia Normal arterial tension with or without inotropic treatment Vital signs stable or easily normalized after nursing care Absence of frequent (>3/hour) and profound (any apnea requiring positive pressure ventilation in the last three hours) apnea

    b. Data Recording: Feeding details at discharge (Exclusive mothers'milk, ≥ 50% mothers' milk, \< 50% mothers' milk, Formula) and data regarding outcomes (sepsis, intraventricular hemorrhage, necrotizing enterocolitis, duration of hospitalization) will be recorded for patients in the pre-education and post-education groups in each unit. The pre-education group includes infants discharged from the units in the two months prior to training, while the post-education group includes infants discharged from the units between the fourth and sixth months after training. Data collected before and after the intervention will be analyzed.

    c. Sample Size: To determine the sample size, a power analysis was conducted using the OpenEpi program. Assuming a 95% confidence level (1-α), an 80% test power (1-β), and an expected effect size of d=0.25, it was determined that at least 59 samples are required in each group.

02

Conditions studied

  • Premature
  • Skin to Skin Contact
  • Breast Feeding
  • Necrotizing Enterocolitis
  • Retinopathy of Prematurity

Keywords

  • Premature
  • Skin to skin contact
  • Breast Feeding
  • Necrotizing Enterocolitis
  • Retinopathy of Prematurity
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 120 is above the median of 84 across 1,666 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Baskent University Ankara Hospital is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born at gestational age ≤ 32 weeks

Exclusion criteria

Exclusion Criteria:

  • Death before NICU discharge
  • Abdominal wall defects
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Pre education

    The infants born at less than 32 weeks and discharged from the units in the last two months before training.

  • Active comparator
    Post education

    The infants born at less than 32 weeks and discharged between four to six months after training

    Behavioral: skin to skin contact care

Interventions

  • Behavioralskin to skin contact care

    Early and regular skin to skin contact in NICU GA: \< 28 weeks: After the 72nd hour GA: 28 - 32 weeks: As soon as stabilization is ensured

06

What researchers measure

Primary outcomes

  1. Mothers' Milk at Discharge

    Number of infants receiving Exclusive Mothers' Milk at Discharge

    Time frame: Through study completion, an average of 3 months, at the time of discharge

Secondary outcomes

  1. Intraventricular hemorrhage

    Number of infants with intraventricular hemorrhage diagnosed by cranial ultrasound

    Time frame: Through study completion, an average of 3 months, at the time of discharge

  2. Necrotizing enterocolitis (stage 2 and above)

    Number of infants with necrotizing enterocolitis (stage 2 and above) according to Bell's criteria

    Time frame: Through study completion, an average of 3 months, at the time of discharge

  3. Early neonatal sepsis

    Number of infants with sepsis within first three days of admission; culture positive or clinical

    Time frame: Through study completion, an average of 3 months, at the time of discharge

  4. Late neonatal sepsis

    Number of infants with sepsis after the third day of admission; culture positive or clinical

    Time frame: Through study completion, an average of 3 months, at the time of discharge

  5. Length of hospital stay

    Total length of hospital stay

    Time frame: Through study completion, an average of 3 months, at the time of discharge

07

Study locations

1 of 1 sites recruiting
  • Baskent University
    Ankara, Turkey
    Recruiting
    • Sezin Unal · Contactsezinunal@gmail.com · 0090532
    • Canan SEREN, MD · Principal investigator
    • Nejat NARLI, MD · Principal investigator
    • Hilal Özkan, MD · Principal investigator
    • Barış AKCAN, MD · Principal investigator
    • Özge SERÇE PEHLİVAN, MD · Principal investigator
    • Beyza ÖZCAN, MD · Principal investigator
    • Ebru YÜCESOY BAĞDİKEN, MD · Principal investigator
    • Gökçe ÇIPLAK, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2025, 7 months after the start.

Of 741 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 7 months is below that.

Counting every sponsor, half of 759 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Nov 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672913
Lead sponsor
Baskent University Ankara Hospital
Responsible party
Sezin Unal (Prof, MD, Baskent University Ankara Hospital) — Principal investigator
First posted
Nov 4, 2024
Start date
Sep 1, 2024
Primary completion
Apr 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Nov 4, 2024

Study contacts

Sezin Unal, Prof, MD
Contact
sezinunal@gmail.com
00905324008018
Esin Koc, Prof, MD
study chair · Gazi University
Saadet Arsan, Prof, MD
study director · Ankara University
Hülya Bilgen, Prof, MD
study director · Marmara University
İlke Mungan Akın, Prof, MD
study director · Umraniye Teaching and Research Hospital
Betül Acunaş, Prof, MD
study director · Trakya University
Mehmet Yalaz, Prof, MD
study director · Ege University
Sezin Unal, Prof, MD
study director · Baskent University
Sule Yigit, Prof, MD
study director · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion